- ¥180bn
- ¥206bn
- ¥247bn
Table: H.U. Group Holdings - 9-MTH group results
Table: H.U. Group Holdings - 6-MTH group results
Table: H.U. Group Holdings -Q1 group results
Table: H.U. Group Holdings -2022/23 parent results
Table: H.U. Group Holdings -2022/23 group results
Table: H.U. Group Holdings - 9-MTH group results
Brief: H.U. Group Holdings Subsidiary Fujirebio Has Received Production, Sales Approval For Coronavirus, Influenza Simultaneous Test Kit Espline Sars-Cov-2&Flu A+B From Japan's Health Ministry
Table: H.U. Group Holdings - 6-MTH group results
Table: H.U. Group Holdings -Q1 group results
Table: H.U. Group Holdings -2021/22 parent results
Table: H.U. Group Holdings -2021/22 group results
Table: H.U. Group Holdings - 9-MTH group results
Table: H.U. Group Holdings - 6-MTH group results
Table: H.U. Group Holdings -Q1 group results
Table: H.U. Group Holdings -2020/21 group results
Table: H.U. Group Holdings -2020/21 parent results
Table: H.U. Group Holdings - 9-MTH group results
Table: H.U. Group Holdings - 6-MTH group results
Table: H.U. Group Holdings, Inc. -2020 6-month group forecast